Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of American Academy of Dermatology

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JAAD.2005.08.025PMID 16635677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

  2004cited by this paper
• Lupus erythematosus with leflunomide: induction or reactivation?

  2004cited by this paper
• Efalizumab in the treatment of psoriasis

  2004cited by this paper
• Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al.

  2002cited by this paper
• Methotrexate treatment for refractory subacute cutaneous lupus erythematosus.

  2002cited by this paper
• Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death

  2002cited by this paper
• Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil

  2002cited by this paper
• Etanercept-induced subacute cutaneous lupus erythematosus.

  2001cited by this paper
• Serum interleukin-15 is elevated in systemic lupus erythematosus.

  2001cited by this paper
• Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy.

  2000cited by this paper
• Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.

  1997cited by this paper
• Guidelines of care for cutaneous lupus erythematosus

  1996cited by this paper
• Guidelines of care for cutaneous lupus erythematosus. American Academy of Dermatology.

  1996cited by this paper
• Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.

  1996cited by this paper
• Clofazimine: a review of its medical uses and mechanisms of action.

  1995cited by this paper
• The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.

  1994cited by this paper
• Profiles of Cytokines (TNFα and IL-6) and Acute Phase Proteins (CRP and α1AG) related to the Disease Course in Patients with Systemic Lupus Erythematosus

  1993cited by this paper
• Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus.

  1993cited by this paper
• Subacute cutaneous lupus erythematosus.

  1993cited by this paper
• Tumor necrosis factor in the serum of patients with systemic lupus erythematosus.

  1989cited by this paper
• Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus.

  1986cited by this paper
• Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin)

  1986cited by this paper
• Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset.

  1979cited by this paper

• Skin

  2021cites this paper
• Clinical improvement upon rituximab treatment in a patient with verrucous cutaneous discoid lupus erythematous in a patient

  2018cites this paper
• Kutaner Lupus erythematodes

  2013cites this paper
• Cutaneous lupus erythematosus

  2012cites this paper
• Chapter 41 – Skin

  2011cites this paper
• Cutaneous lupus erythematosus : Update of therapeutic options Part II

  2011cites this paper
• Cutaneous lupus erythematosus: update of therapeutic options part I.

  2011cites this paper
• T Cell Inhibitors for the Treatment of Psoriasis

  2011cites this paper
• Atopic dermatitis: epidemiology & off-label therapy

  2011cites this paper
• Efalizumab

  2011cites this paper
• Cutaneous lupus erythematosus: update of therapeutic options part II.

  2011cites this paper
• 3 – The lichenoid reaction pattern (‘interface dermatitis’)

  2010cites this paper
• Off-label use of efalizumab in dermatology

  2010cites this paper
• Erfolgreiche Therapie eines diskoiden Lupus erythematodes mit Efalizumab

  2010cites this paper
• Treatment of cutaneous lupus erythematosus

  2010cites this paper
• The ‘Connective Tissue Diseases’

  2010cites this paper
• Off-label use of efalizumab

  2010cites this paper
• Antibody-based therapies in systemic lupus erythematosus.

  2009cites this paper
• Lichenoid Tissue Reaction/Interface Dermatitis: Clinical and Histological Perspectives

  2009cites this paper
• Biologic Therapies In Systemic Lupus Erythematosus

  2009cites this paper
• EFALIZUMAB-INDUCED ISOLATED CEREBRAL LUPUS-LIKE SYNDROME

  2009cites this paper
• Refractory discoid lupus erythematosus: response to efalizumab

  2009cites this paper
• Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives.

  2009cites this paper
• Efalizumab for subacute cutaneous lupus: report of two different outcomes

  2009cites this paper
• Cutaneous Lupus Erythematosus

  2009cites this paper
• [Refractory subacute cutaneous lupus erythematosus with a response to efalizumab].

  2009cites this paper
• Presentation of Syringomas and Lichen Amyloid as a Reactive Dermatosis

  2009cites this paper
• Lupus eritematoso cutáneo subagudo refractario con respuesta a efalizumab

  2009cites this paper
• Kutaner Lupus Erythematodes

  2008cites this paper
• Efalizumab-induced lupus-like syndrome.

  2008cites this paper
• [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].

  2008cites this paper
• Abnormal DNA methylation in T cells from patients with subacute cutaneous lupus erythematosus

  2008cites this paper
• Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab

  2008cites this paper
• Cicatricial alopecia: discoid lupus erythematosus

  2008influential citation
• Generalized pruritus as presentation of T‐cell large granular lymphocyte leukaemia

  2008cites this paper
• Emerging Biological Therapies in Systemic Lupus Erythematosus

  2008cites this paper
• Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

  2008cites this paper
• Complications and adverse reactions in the use of newer biologic agents.

  2007cites this paper
• Efalizumab

  2007cites this paper
• Clinical Use of Immunosuppressive Drugs to Control the Immune Response

  2007cites this paper
• Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective.

  2007cites this paper
• Identification of type I interferon‐associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches

  2007cites this paper
• Efalizumab in the treatment of discoid lupus erythematosus.

  2007cites this paper
• Lupus erythematosus: systemic and cutaneous manifestations.

  2006cites this paper